- Home
- NMCO vs PLRX Comparison
NMCO vs PLRX Comparison
Compare NMCO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- PLRX
- Stock Information
- Founded
- NMCO 2019
- PLRX 2015
- Country
- NMCO United States
- PLRX United States
- Employees
- NMCO N/A
- PLRX N/A
- Industry
- NMCO Finance/Investors Services
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- PLRX Health Care
- Exchange
- NMCO Nasdaq
- PLRX Nasdaq
- Market Cap
- NMCO 577.1M
- PLRX 84.7M
- IPO Year
- NMCO N/A
- PLRX 2020
- Fundamental
- Price
- NMCO $10.78
- PLRX $1.29
- Analyst Decision
- NMCO
- PLRX Hold
- Analyst Count
- NMCO 0
- PLRX 10
- Target Price
- NMCO N/A
- PLRX $9.79
- AVG Volume (30 Days)
- NMCO 207.6K
- PLRX 1.5M
- Earning Date
- NMCO 01-01-0001
- PLRX 08-06-2025
- Dividend Yield
- NMCO 5.43%
- PLRX N/A
- EPS Growth
- NMCO N/A
- PLRX N/A
- EPS
- NMCO N/A
- PLRX N/A
- Revenue
- NMCO N/A
- PLRX N/A
- Revenue This Year
- NMCO N/A
- PLRX N/A
- Revenue Next Year
- NMCO N/A
- PLRX N/A
- P/E Ratio
- NMCO N/A
- PLRX N/A
- Revenue Growth
- NMCO N/A
- PLRX N/A
- 52 Week Low
- NMCO $8.52
- PLRX $1.10
- 52 Week High
- NMCO $11.64
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- NMCO 65.70
- PLRX 43.30
- Support Level
- NMCO $10.76
- PLRX $1.13
- Resistance Level
- NMCO $10.91
- PLRX $1.43
- Average True Range (ATR)
- NMCO 0.13
- PLRX 0.11
- MACD
- NMCO 0.03
- PLRX -0.01
- Stochastic Oscillator
- NMCO 76.79
- PLRX 37.57
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.